Control of sympathetic activity-new insights; New therapeutic targets?

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1048-1050

  Ritz, Eberhard ^a   Rump, Lars Christian ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; IMIDAZOLINE; MOXONIDINE; NIFEDIPINE; NORADRENALIN;

BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG TARGETING; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPATHETIC TONE; TELEMETRY;

ANIMALS; EYE PROTEINS; GTP-BINDING PROTEIN REGULATORS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MICE; PHOSPHOPROTEINS; SYMPATHETIC NERVOUS SYSTEM;

EID: 77950207593     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq079     Document Type: Short Survey

References (27)

1. Beetz N, Harrison MD, Brede M, et al. Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. J Clin Invest 2009; 119: 3597-3612
2. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-1336
3. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678
4. Cowley AW Jr. The genetic dissection of essential hypertension. Nat Rev Genet 2006; 7: 829-840
5. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281
6. Vonend O, Okonek A, Stegbauer J, et al. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. Cardiovasc Res 2005; 66: 345-352
7. Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008; 19: 2047-2051
8. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850
9. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18
10. Hsu CY, McCulloch CE, Darbinian J, et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165: 923-928
11. Ritz E, Bakris G. World Kidney Day: hypertension and chronic kidney disease. Lancet 2009; 373: 1157-1158
12. Strojek K, Grzeszczak W, Gorska J, et al. Lowering of microalbumi-nuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001; 12: 602-605
13. Bohmann C, Schollmeyer P, Rump LC. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 118-124
14. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in sub-totally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-1478
15. Veelken R, Vogel EM, Hilgers K, et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 2008; 19: 1371-1378
16. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20: 933-939
17. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-727
18. Converse RL Jr., Jacobsen TN, Toto RD, et al. Sympathetic overac-tivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
19. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328
20. Klein IH, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-2433
21. Li G, Xu J, Wang P, et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 2008; 117: 1277-1282
22. Desir GV. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int 2009; 76: 366-370
23. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta block-ers. Kidney Int 2001; 60: 1309-1323
24. Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-1717
25. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979
26. Vonend O, Rump LC, Ritz E. Sympathetic overactivity-the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 2008; 21: 326-330
27. Penne EL, Neumann J, Klein IH, et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22: 208-215